From the University of Rochester School of Medicine, Rochester, NY.
In this issue of THE JOURNAL, Downs et al1
present the primary results of the Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS). The study is yet another randomized, placebo-controlled,
clinical trial of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor, in this case lovastatin, as a means to prevent atherosclerotic
coronary artery disease. Although readers might wonder what such a trial might
add to understanding the role of lipid-lowering therapy in general, or of
the use of the so-called statins in particular, this trial is of singular
importance and timeliness to guide the use of these agents in the controversial
area of the primary prevention of cardiovascular disease.
Pearson TA. Lipid-Lowering Therapy in Low-Risk Patients. JAMA. 1998;279(20):1659-1661. doi:10.1001/jama.279.20.1659